Viewing nowAlmantin 20 mg (Memantine Hydrochloride)
Memantine Hydrochloride 20mg
Tablet · Prescription medication
Aliko Pharmaceutical Co., Ltd.

MFDS item code 202500202 · Approved 2025.01.24 · Insurance code 656005670
Treatment of moderate to severe Alzheimer's disease
This medication is used for the treatment of moderate to severe Alzheimer's disease.
Treatment must be initiated by a physician experienced in the diagnosis and treatment of Alzheimer’s dementia, and only if a caregiver can regularly check that the patient is taking the medication. The diagnosis should be made according to currently accepted guidelines. The clinical benefit of this medication and the patient’s tolerability of treatment should be regularly reassessed. This medication is administered orally once daily, at the same time each day. If necessary, it may be administered twice daily. It may be taken with or without food. 1. Adults Dose titration: The maximum daily dose is 20mg. To minimize the risk of adverse reactions, increase the dose by 5mg per week over the first 3 weeks as follows to reach the maintenance dose. Week 1 (Days 1–7): Administer 5mg once daily for 7 days. Week 2 (Days 8–14): Administer 10mg once daily for 7 days. Week 3 (Days 15–21): Administer 15mg once daily for 7 days. From Week 4 onward, administer 20mg once daily. Maintenance dose: The recommended maintenance dose is 20mg once daily. 2. Older adults Based on clinical data, the recommended dose for older patients aged 65 years and over is 20mg once daily. 3. Patients with renal impairment No dose adjustment is required in patients with mild renal impairment (creatinine clearance: 50-80 mL/min). In patients with moderate renal impairment (creatinine clearance: 30-49 mL/min), the daily dose should be reduced to 10mg. If the medication is well tolerated after at least 7 days of treatment, the dose may be increased to 20mg once daily according to the standard dose-titration schedule. In patients with severe renal impairment (creatinine clearance: 5-29 mL/min), the daily dose should be reduced to 10mg. 4. Patients with hepatic impairment No dose adjustment is required in patients with mild or moderate hepatic impairment (Child-Pugh A, Child-Pugh B). Since no data are available on the use of memantine in patients with severe hepatic impairment, it is preferable not to administer this medication.
This drug should not be used by patients with hypersensitivity to its components or with severe liver or kidney dysfunction. Caution is needed for patients with epilepsy or a history of seizures, and the risk of side effects may increase when used in combination with certain NMDA antagonists. Patients with conditions that may increase urine pH or those who have had recent heart disease should use this medication more carefully. This drug contains a dye called Yellow No. 5, so patients allergic to this component should exercise caution. Side effects such as dizziness, headache, constipation, drowsiness, and hypertension may occur, and in severe patients, hallucinations or psychotic reactions have also been reported. As this drug can interact with other medications, it is important to consult with healthcare professionals when used in combination with NMDA antagonists, antipsychotic drugs, muscle relaxants, anticoagulants, etc. Women who are pregnant or may become pregnant should carefully consider the risks and benefits of using this medication, and it is recommended to discontinue breastfeeding if nursing. The safety and efficacy in pediatric patients under 18 years of age have not been established, so it is advisable not to use in this population. In case of overdose, central nervous system symptoms such as confusion, drowsiness, hallucinations, seizures, and gastrointestinal symptoms may occur, requiring immediate medical attention. This drug may slow down the patient's reaction time, so caution is needed when driving or operating machinery. Finally, store it out of reach of children and do not transfer it to other containers, ensuring proper quality maintenance during storage.
Not everyone experiences these, and they can vary from person to person.
This drug should be stored in a tightly sealed container to prevent exposure to air or moisture. It is advisable to maintain a storage temperature between 1°C and 30°C.
Orange, rectangular film-coated tablet
100 tablets/bottle, 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowMemantine Hydrochloride 20mg
Tablet · Prescription medication
Aliko Pharmaceutical Co., Ltd.
Memantine Hydrochloride 1g
Solution · Prescription medication
Lundbeck Korea Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Lundbeck Korea Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Ildong Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Donghwa Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Youngjin Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Unimed Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Myongin Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.